A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Phase 3
Not yet recruiting
- Conditions
- Bstructive Sleep Apnea (OSA) and Obesity
- Interventions
- Drug: HRS9531placebo
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06974851
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
Phase 1
Not yet recruiting
- Conditions
- ObesityOverweight
- Interventions
- Drug: HRS-5817 InjectionDrug: HRS-5817 Injection Placebo
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT06934408
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical Uniersity, Hefei, Anhui, China
Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects
Phase 1
Not yet recruiting
- Conditions
- Type 2 Diabetes MellitusWeight Loss
- Interventions
- Drug: [14C]HRS9531
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT06855147
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Efficacy and Safety of HRS9531 Tablet in Obese Subjects
Phase 2
Recruiting
- Conditions
- Chronic Management of Body Weight
- Interventions
- Drug: HRS9531 TabletDrug: HRS9531 Tablet placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06841445
- Locations
- 🇨🇳
Nanjing Drum Tower hospital, Nanjing, Jiangsu, China
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06792955
- Locations
- 🇨🇳
Central Hospital Affiliated To Shandong First Medical University, Jinan, Shandong, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Overweight or Obesity
- Interventions
- Drug: HRS-4729 injectionDrug: HRS-4729 injection placeboDrug: HRS9531 injection placebo
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT06762600
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06732154
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06723691
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06654960
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
Phase 3
Recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: HRS9531 Placebo Injection
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT06650007
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath